RT Journal Article
SR Electronic
T1 Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6699
OP 6712
DO 10.21873/anticanres.14693
VO 40
IS 12
A1 YUKI NIWA
A1 MAKOTO ASANO
A1 TAKAYUKI NAKAGAWA
A1 DAMIEN FRANCE
A1 TARO SEMBA
A1 YASUHIRO FUNAHASHI
YR 2020
UL http://ar.iiarjournals.org/content/40/12/6699.abstract
AB Background/Aim: There is no established standard chemotherapy after administration of the combination endocrine plus CDK4/6 inhibitor therapy for luminal-type breast cancer. We used patient-derived xenograft (PDX) models to determine the antitumor activity of eribulin and capecitabine after endocrine therapy plus CDK4/6 inhibitor. Materials and Methods: We examined the antitumor activity of fulvestrant, palbociclib, eribulin, and capecitabine in 4 luminal-type breast cancer PDX models (OD-BRE-0188, -0438, -0450, -0745). In OD-BRE-0438, we determined the antitumor activity of chemotherapy after fulvestrant–palbociclib treatment. We also performed immunohistochemical analysis to explore the effects of treatment on E-cadherin in tumor tissues. Results: Fulvestrant, fulvestrant-palbociclib and chemotherapy had antitumor activity in the 4 PDX models. In OD-BRE-0438 (the most resistant to fulvestrant–palbociclib), eribulin had superior antitumor activity to capecitabine after fulvestrant plus palbociclib. Only eribulin tended to increase E-cadherin expression. Conclusion: Eribulin had superior antitumor activity to capecitabine after fulvestrant–palbociclib in the OD-BRE-0438 model.